Picture of United Therapeutics logo

UTHR — United Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

United Therapeutics Corp reports results for the quarter ended in March - Earnings Summary

* United Therapeutics Corp  UTHR.OQ  reported quarterly
adjusted
earnings of $6.17​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $4.86.  The mean expectation of
thirteen analysts for the quarter was for earnings of $5.65 per
share. Wall Street expected results to range from $4.75 
to $6.54 per share.
    * Revenue rose 33.7% to $677.70 million from a year ago;
analysts
expected $623.97 million. 
    * United Therapeutics Corp's reported EPS for the quarter
was
$6.17​.
    * The company reported quarterly net income of $306.6
million.
    * United Therapeutics Corp shares had risen by 2.0% this
quarter and gained 6.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for United
Therapeutics Corp is $304.29 
This summary was machine generated from LSEG data May 1 at 01:32
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      5.65           6.17           Beat
 Dec. 31 2023      4.19           4.36           Beat
 Sep. 30 2023      5.04           5.38           Beat
 Jun. 30 2023      4.51           5.24           Beat

Recent news on United Therapeutics

See all news